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GPER is required for the age-dependent impairment of en-
dothelium-dependent, NO-mediated relaxation in the renal 
artery. Restoration of relaxation by a Nox inhibitor in aged 
wild-type but not Gper– /– mice strongly supports a role for 
Nox-derived reactive oxygen species as the underlying 
cause. Pharmacological blockers of GPER signaling may thus 
be suitable to inhibit functional endothelial aging of renal 
arteries by reducing Nox-derived oxidative stress and, pos-
sibly, the associated age-dependent deterioration of kidney 
function.  © 2017 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease affects more than half of adults 
older than 70 years of age, and is strongly associated with 
an increased risk of cardiovascular disease and mortality 
 [1] . Kidney function critically depends on adequate per-
fusion, which is provided by the renal artery. Advanced 
 Keywords 
 Acetylcholine · Angiotensin · Endothelium · GPR30 · NADPH 
oxidase · Nitric oxide · Phenylephrine · Vascular 
 Abstract 
 Aging is associated with impaired renal artery function, 
which is partly characterized by arterial stiffening and a re-
duced vasodilatory capacity due to excessive generation of 
reactive oxygen species by NADPH oxidases (Nox). The 
abundance and activity of Nox depends on basal activity of 
the heptahelical transmembrane receptor GPER; however, 
whether GPER contributes to age-dependent functional 
changes in renal arteries is unknown. This study investigated 
the effect of aging and Nox activity on renal artery tone in 
wild-type and GPER-deficient ( Gper –/– ) mice (4 and 24 months 
old). In wild-type mice, aging markedly impaired endotheli-
um-dependent, nitric oxide (NO)-mediated relaxations to 
acetylcholine, which were largely preserved in renal arteries 
of aged  Gper –/– mice. The Nox inhibitor gp91ds-tat abolished 
this difference by greatly enhancing relaxations in wild-type 
mice, while having no effect in  Gper –/– mice. Contractions to 
angiotensin II and phenylephrine in wild-type mice were 
partly sensitive to gp91ds-tat but unaffected by aging. 
Again, deletion of GPER abolished effects of Nox inhibition 
on contractile responses. In conclusion, basal activity of 
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age is an independent risk factor for the development of 
both vascular and kidney disease  [2] , indicating a strong 
relationship between arterial and renal pathophysiology 
 [3, 4] . In fact, age-dependent stiffening of renal arteries 
due to vascular calcification, fibrosis, inflammation, and 
a reduced vasodilatory capacity is centrally involved in 
detrimental renal changes, such as the development of 
glomerulosclerosis and tubulointerstitial fibrosis  [3–5] .
 A common mediator of age-dependent structural and 
functional organ damage is excessive production of reac-
tive oxygen species (ROS), commonly referred to as “ox-
idative stress”  [6] . Among several cellular sources, ROS 
are mainly generated by NADPH oxidase (Nox) enzymes, 
of which 7 mammalian isoforms have been identified  [7] . 
Nox-dependent regulation of redox-sensitive signaling 
pathways is particularly important in vascular and renal 
pathophysiology mainly involving Nox1, Nox2, and 
Nox4  [7, 8] . In arteries, ROS reduce the bioavailability of 
endothelium-derived nitric oxide (NO) with subsequent 
loss of its vasodilatory, anti-inflammatory, and anti-
thrombotic properties  [9] . At the same time, oxidative 
stress promotes arterial constriction through activators of 
G protein-coupled receptors (GPCRs), such as angioten-
sin and α-adrenergic receptors  [2, 7] . Furthermore, ROS-
induced alterations in cellular signaling pathways have 
been implicated in arterial remodeling and hypertrophy, 
as well as glomerulosclerosis, tubulointerstitial fibrosis, 
and proteinuria  [7, 8] . Thus, therapeutic approaches in-
terfering with increased ROS formation will likely reduce 
the progression both vascular and renal diseases associ-
ated with aging  [7, 8, 10] .
 We have recently identified an unexpected role of a 
basally active GPCR termed GPER, a heptahelical trans-
membrane receptor that also signals via estrogen-depen-
dent mechanisms  [11] , which is required for Nox1 ex-
pression and activity in the aorta and hearts of aged mice, 
as well as in human aortic smooth muscle cells  [12] . Li-
gand-independent GPER activity was also found to medi-
ate Nox1-dependent impaired vascular function in arte-
rial hypertension  [12] ; however, whether GPER contrib-
utes to age-dependent functional changes of renal arteries 
is unknown.
 We hypothesized that basal GPER activity contributes 
to the deterioration of renal artery function with age in-
volving Nox-dependent mechanisms. To this end, we 
studied the effects of GPER deletion and Nox activity on 
endothelium-dependent, NO-mediated vasodilation and 
vasoconstrictor responses mediated by angiotensin AT 1 
and α-adrenergic receptors in the renal artery from young 
and aged male mice.
 Methods 
 Transgenic Mice and Aging Model 
 Gper –/– mice were generated and backcrossed as described  [12] . 
Male wild-type C57BL/6 and  Gper –/– mice were housed at the An-
imal Resource Facility of the University of New Mexico Health 
Sciences Center under controlled temperature (22   °   C) on a 12-h 
light-dark cycle with unrestricted access to water and a rodent diet 
devoid of alfalfa or soybean meal to minimize the presence of nat-
ural phytoestrogens (Teklad 2020SX, Harlan Laboratories, Madi-
son, WI, USA). Animals were killed by intraperitoneal injection of 
sodium pentobarbital (2.2 mg/g body weight) at 4 and 24 months 
of age, because age-dependent functional and structural changes 
in 24-month-old mice closely resemble human vascular aging  [13] . 
All procedures were approved by and carried out in accordance 
with institutional policies and the National Institutes of Health 
(NIH) Guide for the Care and Use of Laboratory Animals. 
 Preparation of Renal Arteries 
 Immediately after sacrifice, renal arteries were carefully excised 
and dissected free from adherent connective tissue and fat in cold 
(4  °  C) physiological saline solution (PSS; composition in mmol/L: 
129.8 NaCl, 5.4 KCl, 0.83 MgSO 4 , 0.43 NaH 2 PO 4 , 19 NaHCO 3 , 
1.8  CaCl 2 , and 5.5 glucose; pH 7.4). Using two 25 μm tungsten 
wires, vessels were mounted in organ chambers of a Mulvany-
Halpern myograph (620 M Multi-Channel Myograph System, 
Danish Myo Technology, Aarhus, Denmark) containing PSS 
(37  °  C, pH 7.4, bubbled with 21% O 2 , 5% CO 2 , and balanced N 2 ).
 Vascular Reactivity Studies 
 Recordings of isometric tension were performed as described 
 [14] using a PowerLab 8/35 data acquisition system and LabChart 
Pro software (AD Instruments, Colorado Springs, CO, USA). 
Briefly, arteries were stretched stepwise to the optimal level of pas-
sive tension for force generation, and the functional integrity of 
vascular smooth muscle was confirmed by repeated exposure to 
KCl (PSS with substitution of 60 mmol/L potassium for sodium). 
In subsequent experiments, the role of NADPH oxidase was stud-
ied by randomly treating the left or right renal artery with the 
Nox1/2-selective inhibitor gp91ds-tat (3 μmol/L for 30 min)  [15] . 
This peptide is derived from a gp91 phox (now termed Nox2) se-
quence in the region that interacts with the organizer protein 
p47 phox , thus disrupting p47 phox binding to and activation of the 
homologous Nox2 and Nox1 catalytic subunits  [7, 12] . To study 
endothelium-dependent, NO-mediated relaxations, arteries were 
precontracted with phenylephrine to  ∼ 70% of KCl-induced con-
tractions, and responses to acetylcholine (0.1 nmol/L–10 μmol/L) 
were recorded. Precontraction did not differ between groups. Sim-
ilarly, responses to the NO donor sodium nitroprusside (10 μmol/L) 
were determined. Contractions to agonists of angiotensin AT 1 and 
α-adrenergic receptors, angiotensin II (100 nmol/L), and phenyl-
ephrine (0.3 μmol/L), respectively, were studied in separate ex-
periments.
 Calculations and Statistical Analyses 
 Relaxation is expressed as the percentage of precontraction, 
and contraction is given as the percentage of contraction com-
pared to KCl. EC 50 values (given as negative logarithm: pD 2 ), area 
under the curve (given as arbitrary units), and maximal responses 
(E max ) were calculated by non-linear regression analysis  [16] . Data 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
0/
18
/2
01
7 
4:
44
:4
8 
PM
 Meyer/Rosemann/Barton/Prossnitz Pharmacology 2017;100:188–193
DOI: 10.1159/000478732
190
were analyzed by 1-way or 2-way analysis of variance, as appropri-
ate, followed by the Bonferroni post hoc test to correct for multiple 
comparisons (GraphPad Prism version 5.0 for Macintosh, 
 GraphPad Software, San Diego, CA, USA). Values are expressed 
as means ± SEM;  n equals the number of animals per group. Sta-
tistical significance was accepted at a  p value <0.05.
 Drugs 
 Gp91ds-tat was from AnaSpec (Fremont, CA, USA), and so-
dium nitroprusside was from MP Biomedicals (Solon, OH, USA). 
All other drugs were from Sigma-Aldrich (St. Louis, MO, USA). 
Stock solutions were prepared according to the manufacturer’s in-
structions, and diluted in PSS to the required concentrations be-
fore use.
 Results 
 GPER Deletion Preserves Renal Artery NO Bioactivity 
with Aging 
 In renal arteries of young wild-type and  Gper –/– mice, 
endothelium-dependent, NO-mediated relaxation in-
duced by acetylcholine was similar and unaffected by the 
Nox1/2 inhibitor gp91ds-tat ( Fig. 1 ). By contrast, in wild-
type mice, aging markedly reduced endothelium-depen-
dent relaxation (E max , –27 ± 9 vs. –75 ± 10%,  n  = 4–5,  p < 
 0.001 vs. young;  Fig. 1 ), also indicated by reduced sensi-
tivity (pD 2 , 6.4 ± 0.2 vs. 7.4 ± 0.2,  n  = 4–5,  p <  0.01 vs. 
young) and area under the curve values (0.4 ± 0.2 vs. 1.9 ± 
0.4,  n  = 4–5,  p <  0.01 vs. young). This age-dependent de-
terioration in NO bioactivity was largely absent in mice 
lacking  Gper (Emax, –61 ± 8 vs. –27 ± 9%,  n  = 4–5,  p <  0.01 
vs. wild-type;  Fig. 1 ). As a result, vasodilatory responses 
were 2.3-fold greater in aged  Gper –/– mice. The Nox1/2 
inhibitor gp91ds-tat abolished this difference by greatly 
enhancing relaxation in aged wild-type mice (2.3-fold, 
from –27 ± 9 to –63 ± 11%,  n  = 5,  p <  0.01), to the level 
observed in  Gper –/– mice (–61 ± 8%). Furthermore, gp-
91ds-tat had no effect in  Gper –/– mice ( Fig. 1 ). Vasodila-
tion in response to the exogenous NO donor sodium 
 nitroprusside was unaffected by aging or  Gper deletion, 
indicating that the differences observed in acetylcholine-
mediated relaxation are not due to alterations in the sen-
sitivity to NO (not shown). Thus, aging impairs endothe-
lium-dependent, NO-mediated relaxation in renal arter-
ies largely through increased Nox activity, an effect that 
is absent in mice lacking  Gper .
 GPER Mediates Nox-Dependent Signaling to 
GPCR Agonists 
 Given that  Gper mediates age-dependent, Nox-medi-
ated changes in endothelium-dependent relaxation of 
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 Fig. 1. Effect of aging and GPER on endo-
thelium-dependent relaxation to acetyl-
choline in renal arteries. The role of Nox-
derived oxidative stress was assessed using 
the Nox1/2-inhibitor gp91ds-tat (tat, 
3 μmol/L) in wild-type and  Gper –/– mice at 
4 (young) or 24 (aged) months of age. Re-
sponses are expressed as percent of precon-
traction to phenylephrine (PE). Insets: area 
under the curve (AUC) of the concentra-
tion-response curves given as arbi-
trary units. Data ( n  = 4–5 per group) are 
means ± SEM.  * *   p  < 0.01,  * * *   p  < 0.001 vs. 
young;  ††    p   < 0.01 vs. untreated control 
(CTL);  ‡‡  p  < 0.01 vs. wild-type. 
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renal arteries, we next studied whether similar altera-
tions also exist in contractile responses induced by ago-
nists of other GPCRs. In wild-type mice, contractions to 
angiotensin II were unaffected by aging ( Fig.  2 a); the 
Nox1/2 inhibitor gp91ds-tat reduced contractions to 
angiotensin II in young (1.9-fold) and aged (1.3-fold) 
animals (both  n  = 5–7,  p <  0.05;  Fig. 2 a). Deletion of 
 Gper reduced contractions to Ang II in young mice only 
( ∼ 50% reduction,  n  = 5–7,  p  < 0.01;  Fig. 2 a). Notably, in 
the absence of  Gper , Nox1/2 inhibition had no effect on 
angiotensin II-induced contractions regardless of age 
( Fig. 2 a).
 Aging did not affect contractions to the α-adrenergic 
agonist phenylephrine independent of genotype. How-
ever, responses were partially blocked by gp91ds-
tat in young and aged wild-type (both  ∼ 30%,  n  = 4–7, 
 p <  0.05), but not in  Gper –/– mice ( Fig. 2 b). Together, 
given  that the Nox1/2 inhibitor gp91ds-tat is ineffec-
tive  in  mice lacking the  Gper gene, these findings 
 indicate  that  basal  Gper activity is required for Nox- 
mediated contractions to GPCR agonists in addition to 
the age-dependent impaired NO bioactivity in renal 
 arteries.
 Discussion 
 In the present study, we have sought to characterize 
functional changes in the renal artery during the physi-
ological aging process and to assess whether and how 
GPER, a GPCR recently found to regulate Nox1 protein 
abundance and function  [12] , contributes to ROS-depen-
dent modulation of endothelium-dependent and -inde-
pendent vascular tone. The results show that endotheli-
um-dependent, NO-mediated vasodilation in the renal 
artery is markedly reduced with aging, a functional change 
that largely depends on the activity of both  Gper and Nox. 
These results are compatible with our previous report 
showing that Nox-derived ROS formation is largely ab-
sent in the heart and aorta of aged  Gper –/– mice  [12] . In 
both studies, we used the Nox1/2-selective inhibitor gp-
91ds-tat  [15] , a peptide derived from a gp91 phox (now 
termed Nox2) sequence in the region that interacts with 
the organizer protein p47 phox , thus disrupting p47 phox 
binding to and activation of the homologous Nox2 and 
Nox1 catalytic subunits  [7, 12] . Detailed mechanistic 
studies in murine and human vascular smooth muscle 
cells revealed that GPER in fact selectively regulates Nox1 
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 Fig. 2. Effect of aging and GPER on Nox-
mediated contractions to GPCR agonists in 
renal arteries. Responses were recorded in 
the presence and absence of the Nox1/2-
inhibitor gp91ds-tat (3 μmol/L) in young 
(4 months old) and aged (24 months 
old) wild-type and  Gper –/– mice.  a Contrac-
tions to the angiotensin AT1 receptor ago-
nist  angiotensin II (Ang II, 100 nmol/L). 
 b  Contractions to the α-adrenergic agonist 
phenylephrine (PE, 0.3 μmol/L). Respons-
es are expressed as percent of contraction 
to KCl (60 mmol/L). Data ( n   = 5–7 per 
group) are means ± SEM.  *   p  < 0.05,  * *   p  < 
0.01 vs. untreated control (CTL);  ††   p  < 0.01 
vs. wild-type;  ‡‡   p  < 0.01 vs. young. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
0/
18
/2
01
7 
4:
44
:4
8 
PM
 Meyer/Rosemann/Barton/Prossnitz Pharmacology 2017;100:188–193
DOI: 10.1159/000478732
192
protein abundance and function, while having no effect 
on Nox2  [12] . It is thus highly likely that Nox1, facilitated 
by basal GPER activity, is centrally involved in the age-
dependent regulation of renal artery tone.
 In contrast to the aorta or carotid arteries from young 
mice  [12, 17] , the endothelium-dependent, NO-mediated 
relaxant response induced by acetylcholine was about 
20% less potent in renal arteries, and impaired to an even 
greater extent with aging. Although this age-dependent 
reduction was largely reversed by inhibiting Nox, several 
mechanisms may also play a role. Acetylcholine-depen-
dent generation of cyclooxygenase-derived vasoconstric-
tor prostanoids counteracts the vasodilatory activity of 
NO  [18] , and their formation and activity increases with 
aging  [19] , an effect that may become insensitive to 
Nox1/2 inhibition by gp91ds-tat  [17] . Of note, compared 
to other arterial beds, the renal artery produces higher 
levels of endothelium-derived vasoconstrictor pros-
tanoids  [20] , which are co-stimulated with NO in re-
sponse to acetylcholine. Second, the renal artery may be 
more sensitive to uncoupling of endothelial NO synthase 
compared to other vascular beds, an effect that can be in-
duced by Nox1-derived ROS  [21] . As a result, uncoupled 
endothelial NO synthase increasingly produces ROS in-
stead of vasodilatory NO, which is further reduced by di-
rect interaction with superoxide and hydrogen peroxide 
 [22] .
 We also studied whether and how aging and GPER 
deficiency affect renal artery contractility to GPCR ago-
nists, including angiotensin II and phenylephrine. Pre-
viously, angiotensin II was used to stimulate Nox activ-
ity in vascular smooth muscle cells  [23] and subsequent 
cloning of Nox1  [24] . Indeed, angiotensin II has emerged 
as the prototypic inducer of Nox1 both at the molecular 
and functional level  [7] . We recently found that, in the 
murine aorta of wild-type mice, contraction to angio-
tensin II (and the ROS formation associated with it) is 
partially sensitive to inhibition by gp91ds-tat; of note, 
mice lacking GPER showed an equal reduction in con-
traction to angiotensin II, with gp91ds-tat having no ad-
ditional effect, indicating that Nox-dependent contrac-
tions to angiotensin II require functional GPER  [12] . 
The present study extends these findings, showing a 
similar regulation of angiotensin II-dependent contrac-
tions by GPER in the renal artery, suggesting a common 
mechanism in different vascular beds that persists inde-
pendent of age. Furthermore, contractions to the 
α-adrenergic agonist phenylephrine were partly medi-
ated by GPER-dependent Nox activity, indicating that 
the ROS-dependent regulation of vascular tone by GPER 
is not limited to a specific agonist, but may be involved 
in a broader number of signaling pathways governed by 
Nox1.
 The present study was conducted in male animals to 
exclude any effects of endogenous (ovarian) estrogen, the 
prototypical physiological GPER agonist  [11] . The data 
reinforce that ligand-independent or basal activity of 
GPER affects regulation of vascular tone, consistent with 
our previous studies  [12, 25, 26] . Indeed, many GPCRs 
exhibit basal or intrinsic activity sufficient to regulate cell 
signaling  [27] . Furthermore, effects reported in the pres-
ent study are independent of blood pressure, as both wild-
type and GPER-deficient mice at 3 and 24 months of age, 
respectively, remain normotensive  [12, 17] .
 In conclusion, this study shows that aging substan-
tially attenuates endothelium-dependent, NO-mediat-
ed relaxation in the renal artery, which is largely pre-
served in GPER-deficient mice due to a lack of Nox ac-
tivity. These findings indicate a novel role for GPER in 
ROS-dependent functional aging of the renal artery. 
With the availability of small molecule GPER blockers 
such as G36  [28] , which represent a new drug class ca-
pable of selectively reducing the increased expression 
and activity of Nox1 [12], future therapeutic applica-
tions in disease conditions characterized by oxidative 
stress may emerge  [29] . Inhibition of GPER signaling 
may thus provide a novel approach to inhibit the age-
dependent impairment of renal artery function and, 
possibly, the associated detrimental structural and func-
tional renal changes.
 Acknowledgments 
 This study was supported by NIH R01 grants (CA127731, 
CA163890 and CA194496 to E.R.P.), the UNM Comprehensive 
Cancer Center (NIH grant P30 CA118100), Dedicated Health Re-
search Funds from the UNM School of Medicine allocated to the 
Signature Program in Cardiovascular and Metabolic Diseases (to 
E.R.P.), a grant from Dialysis Clinic, Inc. (to E.R.P.), and the Swiss 
National Science Foundation (grants 135874 and 141501 to 
M.R.M., and grants 108258 and 122504 to M.B.). The authors 
thank Jan S. Rosenbaum (Proctor & Gamble, Cincinnati, OH, 
USA) for providing GPER-deficient mice.
 Disclosure Statement 
 M.R.M., M.B., and E.R.P. are inventors on a US patent applica-
tion for the therapeutic use of compounds targeting GPER. E.R.P. 
is an inventor on US patent Nos. 7,875,721 and 8,487,100 for 
GPER-selective ligands and imaging agents.  
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
0/
18
/2
01
7 
4:
44
:4
8 
PM
 GPER and Renal Artery Aging Pharmacology 2017;100:188–193
DOI: 10.1159/000478732
193
 References 
 1 Levey AS, Inker LA, Coresh J: Chronic kidney 
disease in older people. JAMA 2015; 314: 557–
558. 
 2 Barton M, Husmann M, Meyer MR: Acceler-
ated vascular aging as a paradigm for hyper-
tensive vascular disease: prevention and ther-
apy. Can J Cardiol 2016; 32: 680–-686.e4. 
 3 Jia G, Aroor AR, Sowers JR: Arterial stiffness: 
a nexus between cardiac and renal disease. 
Cardiorenal Med 2014; 4: 60–71. 
 4 Huang N, Foster MC, Mitchell GF, Andres-
dottir MB, Eiriksdottir G, Gudmundsdottir 
H, Harris TB, Launer LJ, Palsson R, Gudna-
son V, Levey AS, Inker LA: Aortic stiffness 
and change in glomerular filtration rate and 
albuminuria in older people. Nephrol Dial 
Transplant 2017; 32: 677–684. 
 5 Bolignano D, Mattace-Raso F, Sijbrands EJ, 
Zoccali C: The aging kidney revisited: a sys-
tematic review. Ageing Res Rev 2014; 14: 65–
80. 
 6 Harman D: Aging: a theory based on free rad-
ical and radiation chemistry. J Gerontol 1956; 
 11: 298–300. 
 7 Lassegue B, San Martin A, Griendling KK: 
Biochemistry, physiology, and pathophysiol-
ogy of NADPH oxidases in the cardiovascular 
system. Circ Res 2012; 110: 1364–1390. 
 8 Holterman CE, Read NC, Kennedy CR: Nox 
and renal disease. Clin Sci (Lond) 2015; 128: 
 465–481. 
 9 Munzel T, Sinning C, Post F, Warnholtz A, 
Schulz E: Pathophysiology, diagnosis and 
prognostic implications of endothelial dys-
function. Ann Med 2008; 40: 180–196. 
 10 Altenhofer S, Radermacher KA, Kleikers PW, 
Wingler K, Schmidt HH: Evolution of 
NADPH oxidase inhibitors: selectivity and 
mechanisms for target engagement. Antioxid 
Redox Signal 2015; 23: 406–427. 
 11 Revankar CM, Cimino DF, Sklar LA, Ar-
terburn JB, Prossnitz ER: A transmembrane 
intracellular estrogen receptor mediates rap-
id cell signaling. Science 2005; 307: 1625–
1630. 
 12 Meyer MR, Fredette NC, Daniel C, Sharma G, 
Amann K, Arterburn JB, Barton M, Prossnitz 
ER: Obligatory role for GPER in cardiovascu-
lar aging and disease. Sci Signal 2016; 9:ra105. 
 13 Lakatta EG: Arterial and cardiac aging: major 
shareholders in cardiovascular disease enter-
prises: part III: cellular and molecular clues to 
heart and arterial aging. Circulation 2003; 107: 
 490–497. 
 14 Meyer MR, Barton M, Prossnitz ER: Func-
tional heterogeneity of NADPH oxidase-me-
diated contractions to endothelin with vascu-
lar aging. Life Sci 2014; 118: 226–231. 
 15 Rey FE, Cifuentes ME, Kiarash A, Quinn MT, 
Pagano PJ: Novel competitive inhibitor of 
NAD(P)H oxidase assembly attenuates vas-
cular O(2)(-) and systolic blood pressure in 
mice. Circ Res 2001; 89: 408–414. 
 16 DeLean A, Munson PJ, Rodbard D: Simulta-
neous analysis of families of sigmoidal curves: 
application to bioassay, radioligand assay, 
and physiological dose-response curves. Am J 
Physiol 1978; 235:E97–E102. 
 17 Meyer MR, Fredette NC, Barton M, Prossnitz 
ER: Prostanoid-mediated contractions of the 
carotid artery become Nox2-independent 
with aging. Age (Dordr) 2015; 37: 9806. 
 18 Vanhoutte PM, Shimokawa H, Feletou M, 
Tang EH: Endothelial dysfunction and vascu-
lar disease – a thirthieth anniversary update. 
Acta Physiol (Oxf) 2017; 219: 22–96. 
 19 Heymes C, Habib A, Yang D, Mathieu E, Ma-
rotte F, Samuel J, Boulanger CM: Cyclo-oxy-
genase-1 and -2 contribution to endothelial 
dysfunction in ageing. Br J Pharmacol 2000; 
 131: 804–810. 
 20 Barton M, Vos I, Shaw S, Boer P, D’Uscio 
LV, Grone HJ, Rabelink TJ, Lattmann T, 
Moreau P, Luscher TF: Dysfunctional renal 
nitric oxide synthase as a determinant of 
salt-sensitive hypertension: mechanisms of 
renal artery endothelial dysfunction and role 
of endothelin for vascular hypertrophy and 
glomerulosclerosis. J Am Soc Nephrol 2000; 
 11: 835–845. 
 21 Dikalova AE, Gongora MC, Harrison DG, 
Lambeth JD, Dikalov S, Griendling KK: Up-
regulation of Nox1 in vascular smooth muscle 
leads to impaired endothelium-dependent re-
laxation via eNOS uncoupling. Am J Physiol 
Heart Circ Physiol 2010; 299:H673–H679. 
 22 Li H, Forstermann U: Uncoupling of endo-
thelial NO synthase in atherosclerosis and 
vascular disease. Curr Opin Pharmacol 2013; 
 13: 161–167. 
 23 Griendling KK, Minieri CA, Ollerenshaw JD, 
Alexander RW: Angiotensin II stimulates 
NADH and NADPH oxidase activity in cul-
tured vascular smooth muscle cells. Circ Res 
1994; 74: 1141–1148. 
 24 Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, 
Sorescu D, Chung AB, Griendling KK, Lam-
beth JD: Cell transformation by the superox-
ide-generating oxidase Mox1. Nature 1999; 
 401: 79–82. 
 25 Meyer MR, Amann K, Field AS, Hu C, Hatha-
way HJ, Kanagy NL, Walker MK, Barton M, 
Prossnitz ER: Deletion of G protein-coupled 
estrogen receptor increases endothelial vaso-
constriction. Hypertension 2012; 59: 507–512. 
 26 Meyer MR, Field AS, Kanagy NL, Barton M, 
Prossnitz ER: GPER regulates endothelin-de-
pendent vascular tone and intracellular cal-
cium. Life Sci 2012; 91: 623–627. 
 27 Martin AL, Steurer MA, Aronstam RS: Con-
stitutive activity among orphan class-A G 
protein coupled receptors. PLoS One 2015; 10: 
 e0138463. 
 28 Dennis MK, Field AS, Burai R, Ramesh C, 
Petrie WK, Bologa CG, Oprea TI, Yamaguchi 
Y, Hayashi S, Sklar LA, Hathaway HJ, Ar-
terburn JB, Prossnitz ER: Identification of a 
GPER/GPR30 antagonist with improved es-
trogen receptor counterselectivity. J Steroid 
Biochem Mol Biol 2011; 127: 358–366. 
 29 Meyer MR, Barton M: GPER blockers as Nox 
downregulators: a new drug class to tar-
get  chronic non-communicable diseases. J 
Steroid Biochem Mol Biol 2017; pii: S0960-
0760(17)30084-5. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
0/
18
/2
01
7 
4:
44
:4
8 
PM
